Angus Worthing, MD
Rheumatology · Washington, DCNPI 1558534925
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 65.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $6,024 and has fallen 70.5% since, to $1,777 in 2025.
Across 60 payments — averaging $149.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- Invivyd Inc$2K
- Organon$434
- Amgen$424
- Johnson & Johnson$133
- AstraZeneca$129
- plus $349 from 12 others
What the payments were for
- Consulting fees$5,30859%
- Speaking & faculty fees$4345%
- Travel & lodging$1,52017%
- Food & beverage$1,68319%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 15 | $5,852 |
| Invivyd Inc | 1 | $1,628 |
| Organon | 1 | $434 |
| Amgen(2 entities) | 9 | $424 |
| Johnson & Johnson | 11 | $133 |
| AstraZeneca | 2 | $129 |
| Pfizer | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Genentech USA, Inc. | 2 | $37 |
| GSK | 2 | $29 |
| Radius Health, Inc. | 2 | $27 |
| Octapharma USA, Inc. | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| AbbVie | 1 | $18 |
| Novartis | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,949 in reported general payments places this provider in the 60th percentile of 41 rheumatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 49 | $442,239 |
| Humira PenAdalimumab | 26 | $236,745 |
| RinvoqUpadacitinib | 29 | $178,381 |
| EnbrelEtanercept | 22 | $176,521 |
| Enbrel MiniEtanercept | 13 | $112,453 |
| Xeljanz XrTofacitinib Citrate | 12 | $75,793 |
| Teriparatide | 30 | $57,931 |
| ForteoTeriparatide | 12 | $57,738 |
| KevzaraSarilumab | 11 | $47,007 |
| ActemraTocilizumab | 13 | $37,594 |
| Hydroxychloroquine Sulfate | 185 | $8,026 |
| MethotrexateMethotrexate Sodium | 224 | $7,640 |
| Febuxostat | 26 | $5,438 |
| Leflunomide | 73 | $4,637 |
| Duloxetine Hcl | 60 | $2,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $18 | $178,38129 claims |
| AmgenEnbrel | $424 | $176,52122 claims |
| Lilly USA, LLCForteo | $13 | $57,73812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 41 rheumatology providers in District of Columbia.
Other rheumatology in Washington
- Stephen MitchellWashington$1.6M
- Andrea Leonard-SegalWashington$633K
- Gail KerrWashington$244K
- Virginia SteenWashington$168K
- Sharon DowellWashington$73K
- Christopher CollinsWashington$69K
- Saira BilalWashington$62K
- Megan LockwoodWashington$23K
- Mercedes QuinonesWashington$23K
- Tayseer HarounWashington$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.